Hypereosinophilia in hodgkin lymphoma

Cyriac, Sanju; Sagar, Tenali Gnana; Rajendranath, Rejiv; Rathnam, Krishnakumar

doi:10.1007/s12288-008-0031-x

Cited by 10 publications

(9 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Eosinophilia is present in 15% of HL at diagnosis. Only rarely HE criteria are also met [ 178 , 179 ]. Furthermore, eosinophilia can be a feature of other chronic lymphoid diseases as well as of acute lymphoblastic leukaemia [ 180 – 183 ], where it can associate with organ damage and affect prognosis.…”

Section: Eosinophils In Haematological Disorders and Cancermentioning

confidence: 99%

Eosinophils from Physiology to Disease: A Comprehensive Review

Ramirez

Yacoub

Ripa

et al. 2018

BioMed Research International

210

198

View full text Add to dashboard Cite

Despite being the second least represented granulocyte subpopulation in the circulating blood, eosinophils are receiving a growing interest from the scientific community, due to their complex pathophysiological role in a broad range of local and systemic inflammatory diseases as well as in cancer and thrombosis. Eosinophils are crucial for the control of parasitic infections, but increasing evidence suggests that they are also involved in vital defensive tasks against bacterial and viral pathogens including HIV. On the other side of the coin, eosinophil potential to provide a strong defensive response against invading microbes through the release of a large array of compounds can prove toxic to the host tissues and dysregulate haemostasis. Increasing knowledge of eosinophil biological behaviour is leading to major changes in established paradigms for the classification and diagnosis of several allergic and autoimmune diseases and has paved the way to a “golden age” of eosinophil-targeted agents. In this review, we provide a comprehensive update on the pathophysiological role of eosinophils in host defence, inflammation, and cancer and discuss potential clinical implications in light of recent therapeutic advances.

show abstract

Section: Eosinophils In Haematological Disorders and Cancermentioning

confidence: 99%

Eosinophils from Physiology to Disease: A Comprehensive Review

Ramirez

Yacoub

Ripa

et al. 2018

BioMed Research International

210

198

View full text Add to dashboard Cite

show abstract

“…The German Hodgkin Lymphoma study group further demonstrated that eosinophilia is of prognostic relevance in nodular sclerosis‐subtype Classical Hodgkin Lymphoma patients, whereas in patients with mixed cellularity‐subtype Hodgkin Lymphoma, the effect on survival was weaker . These observational findings suggest that the prognostic relevance of eosinophils in Hodgkin Lymphoma depends on the specific histological subtype, however, they are not able to offer an explanation for this finding .…”

Section: Summary and Discussion Of The Casementioning

confidence: 94%

“…Even though the presence of a prominent tissue eosinophilia represents a common histopathologic feature of Hodgkin Lymphoma, eosinophils have been mainly regarded as ‘innocent' bystanders recruited and activated during the cellular reaction typical of Hodgkin Lymphoma. Recent research, however, challenges this notion . Eosinophils may act as important elements in the pathology of Hodgkin Lymphoma by providing cellular ligands to the Tumor Necrosis Factor (TNF) superfamily receptors (CD40, CD30, CD95/Fas) expressed on the surface of both Hodgkin and Reed Sternberg cells.…”

Section: Summary and Discussion Of The Casementioning

confidence: 99%

Multi‐system complications of hypereosinophilia

et al. 2016

View full text Add to dashboard Cite

A 60 year-old male Veteran with medical history of COPD, hypertension, and a 45 pack-year smoking history presented to his primary care provider. Routine lab work incidentally showed a 31% eosinophilia, corresponding to a total eosinophil count of 2000/lL. The remainder of a complete blood count at initial and subsequent presentations are shown in Table I. He had no diarrhea, sick contacts, or recent travel. He did not report any food, drug, or seasonal allergies, and his physical exam was unrevealing. He did not have any Agent Orange exposure and had no family history of hematologic malignancy. A limited workup for his eosinophilia included negative stool testing for ova and parasites and a negative Strongyloides antibody.Eosinophilia is defined as an absolute eosinophil count (AEC) in the peripheral blood of 500 eosinophils/mL. Marked eosinophilia refers to a more significant increase in eosinophil counts to 1500 eosinophils/mL. The differential diagnosis for marked eosinophilia is broad and includes primary (clonal), secondary (reactive), and idiopathic causes [1]. This patient's military history, and associated travel to endemic regions, puts him at risk for helminthic infections such as Strongyloidiasis, Toxocariasis, Trichinellosis, and Hookworm. In the general population, other secondary causes include allergic disorders (such as asthma, allergic rhinitis, allergic broncho-pulmonary aspergillosis, eosinophilic esophagitis), drug reactions, adrenal insufficiency, and a variety of rheumatologic diseases [such as dermatomyositis and eosinophilic granulomatosis with polyangiitis (EGPA)]. Worldwide, the most common causes of eosinophilia are parasitic diseases, while in developed countries, allergic processes are most frequent [2]. Primary causes for hypereosinophilia are rare and are due to myeloproliferative or lymphoproliferative disorders. They should be considered when secondary causes have been ruled out.When a patient presents with marked eosinophilia, one should focus on ruling out the most common secondary causes without completing an extensive workup. Initial tests include a complete blood cell count (CBC), blood smear, as well as an assessment of allergies and parasites (with antibodies to Strongyloides and Schistosomiasis as well as stool ova and parasites, if indicated). Screening tests should be done to exclude organ involvement, with attention to cardiac and pulmonary involvement: basic metabolic panel, urinalysis, liver function tests, cardiac biomarkers, and chest radiography. For eosinophilia persisting beyond one month, more extensive diagnostic studies including flow cytometry and consultation with a hematologist are indicated.Our patient remained asymptomatic and presented four months later when he was admitted to an outside hospital with severe left upper quadrant abdominal pain. The pain was accompanied by nausea and non-bloody, non-bilious emesis. CT imaging of the abdomen revealed multiple wedge-shaped splenic infarcts. A workup for splenic infarcts was initiated and included a negativ...

show abstract

“…Eosinophilia and HL association is estimated to be present in 15-38% of all lymphoma patients 4,6 . Its prognostic significance is not entirely clear.…”

Section: Discussionmentioning

confidence: 99%

“…It is well known that reactive eosinophilia appears in lymphoid malignancies. Its frequency is estimated to be about 15% of all Hodgkin`s lymphoma (HL) patients 4 . Reactive eosinophilia is based on treating the underlying condition.…”

Section: Introductionmentioning

confidence: 99%

Eosinophilia as a first sign of Hodgkin´s lymphoma: A case report

et al. 2017

View full text Add to dashboard Cite

Introduction.It is well known that eosinophilia appears in a malignant disease. Frequency of all Hodgkin`s lymphoma patients is estimated to about 15%. Prognostic importance of this phenomenon is not completely investigated. Therefore we decided to present a female patient with eosinophilia, six months before lymphoma appearance. Case report. We presented a 51years old female, from Serbia, who had eosinophilia (1,530-2,040 eosinophils per µL of blood), six months before Hodgkin's lymphoma appearance. Eosinophilic granuloma was confirmed by tumor's biopsy and histopathologic examination, from the right femoral region. As eosinophilia was increasing, lymph nodes became enlarged (120 × 65 mm diameter), in the right parailiac region. All infectious and allergic examinations did not reveal eosinophilia's cause. Histopathologic revision was made with added immunohistochemical stains 17 months after tumor's biopsy. The diagnosis was changed from eosinophilic granuloma to mixed cellularity Hodgkin's lymphoma. After conducted Ann Arbor staging classification, II B clinical stage was established. The treatment was done by chemotherapy according to adriamycin, bleomycin, vinblastine, dacarbarine (ABVD) protocol, with 6 courses. Complete remission of the disease was achieved after 4 courses. Eosinophils number dropped to 640 per μl blood. Conclusion. Eosinophilia without revealed cause can precede Hodgkin's lymphoma. We suggest careful search for enlarged lymph nodes, anywhere in the patients' body who suffer from eosinophilia. Timely and accurate histopathologic diagnostic is a right way to resolve such conditions. Uvod. Dobro je poznato da se eozinofilija može javiti u okviru malignih bolesti. Učestalost je procenjena na oko 15% svih obolelih od Hodžkinovog limfoma. Prognostički značaj ovog fenomena nije u potpunosti razjašnjen. Smatrali smo korisnim da prikažemo bolesnicu sa eozinofilijom koja se javila nekoliko meseci pre pojave Hodžkinovog limfoma. Prikaz bolesnice. Prikazana je bolesnica, stara 51 godinu, iz Srbije, koja je 6 meseci pre pojave Hodžkinovog limfoma imala eozonofiliju (1 530-2 040 eozinofila u μL krvi). Biopsijom i histopatološkim pregledom tumorske promene na desnoj butini postavljena je inicijalna dijagnoza eozinofilnog granuloma. Kako je eozinofiija rasla, došlo je do pojave uvećanih limfnih čvorova, promera 120 × 65 mm u parailijačnom prostoru, desno. Sva infektološka i alergološka ispitivanja nisu ukazala na uzrok eozinofilije. Posle 17 meseci učinjena je revizija histopatološkog nalaza biopsije tumora uz dodatna imunohistohemijska ispitivanja. Dijagnoza je promenjena od eozinofilnog granuloma u Hodžkinov limfom, tipa mešovite celularnosti. Posle sprovedene Ann Arbor "stejdžing" procedure zaključeno je da se radi o II B kliničkom stadijumu Hodžkinovog limfoma. Lečenje je sprovedeno hemioterapijom po protokolu adriamicin, bleomicin, vinblastin, dekarbazin (ABVD) sa 6 ciklusa. Uspostavljena je kompletna remisija bolesti već posle 4 ciklusa. Broj eozinofila se sveo na 640/μL krvi. Zaključak. U retkim sl...

show abstract

Hypereosinophilia in hodgkin lymphoma

Cited by 10 publications

References 5 publications

Eosinophils from Physiology to Disease: A Comprehensive Review

Eosinophils from Physiology to Disease: A Comprehensive Review

Multi‐system complications of hypereosinophilia

Eosinophilia as a first sign of Hodgkin´s lymphoma: A case report

Contact Info

Product

Resources

About